These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 27216253)

  • 1. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
    Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
    Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
    Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
    J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women.
    Gauthier G; Gagnon-Sanschagrin P; Guérin A; Burne R; Small T; Niravath P; Dalal AA
    Adv Ther; 2018 Apr; 35(4):503-514. PubMed ID: 29556908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
    Li N; Hao Y; Kageleiry A; Peeples M; Fang A; Koo V; Wu EQ; Guérin A
    Curr Med Res Opin; 2016; 32(2):385-94. PubMed ID: 26651842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
    Guérin A; Hao Y; Tang D; Peeples M; Fang A; Kageleiry A; Koo V; Li N; Wu EQ
    Expert Opin Pharmacother; 2016 Jun; 17(9):1189-96. PubMed ID: 27052735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
    Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
    Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HR+/HER2- Metastatic Breast Cancer: Epidemiology, Prescription Patterns, Healthcare Resource Utilisation and Costs from a Large Italian Real-World Database.
    Piccinni C; Dondi L; Ronconi G; Calabria S; Pedrini A; Esposito I; Martini N; Marangolo M
    Clin Drug Investig; 2019 Oct; 39(10):945-951. PubMed ID: 31347036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
    Burton T; Byfield SD; Smith GL; Zanotti G; Bell TJ; Perkins JJ; Horblyuk R; Teitelbaum A
    Curr Med Res Opin; 2016 Aug; 32(8):1417-23. PubMed ID: 27074160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
    Houts AC; Olufade T; Shenolikar R; Walker MS; Schwartzberg LS
    Cancer Treat Res Commun; 2019; 19():100121. PubMed ID: 30785027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age.
    Sussell JA; Sheinson D; Wu N; Shah-Manek B; Seetasith A
    Adv Ther; 2020 Apr; 37(4):1632-1645. PubMed ID: 32172510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study.
    Goldschmidt D; Dalal AA; Romdhani H; Kelkar S; Guerin A; Gauthier G; Wu EQ; Niravath P; Small T
    Adv Ther; 2018 Apr; 35(4):482-493. PubMed ID: 29582246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
    Lin PL; Hao Y; Xie J; Li N; Ohashi E; Koo V; Wu EQ
    Expert Opin Pharmacother; 2015; 16(14):2101-11. PubMed ID: 26290278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
    Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
    Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    Quek RGW; Mardekian J
    Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer.
    Li N; Du EX; Chu L; Peeples M; Xie J; Barghout V; Tang DH
    Expert Opin Pharmacother; 2017 Aug; 18(12):1167-1178. PubMed ID: 28699804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites.
    Li N; Hao Y; Xie J; Lin PL; Koo V; Ohashi E; Wu EQ
    Clin Ther; 2016 Apr; 38(4):905-17. PubMed ID: 26947172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
    Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
    Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer.
    Li N; Hao Y; Xie J; Lin PL; Zhou Z; Zhong Y; Signorovitch JE; Wu EQ
    Curr Med Res Opin; 2015 Aug; 31(8):1573-82. PubMed ID: 26074049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
    Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
    Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the healthcare costs of metastatic breast cancer: A retrospective matched cohort study.
    Chen HM; Chen JH; Chiang SC; Lin YC; Ko Y
    Medicine (Baltimore); 2021 Oct; 100(43):e27567. PubMed ID: 34713830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.